CTOs on the Move

Jamol Laboratories

www.ponaris.net

 
Jamol Laboratories is a Emerson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ponaris.net
  • 13 Ackerman Ave
    Emerson, NJ USA 07630
  • Phone: 201.262.6363

Executives

Name Title Contact Details

Similar Companies

Proacta

Proacta is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caribbean Clinical Research ASsociates

Caribbean Clinical Research ASsociates is a East Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jamieson Wellness

Jamieson Wellness is a Canadian company that manufactures, distributes, and markets high quality natural health products. Their portfolio includes the Jamieson brand, which is Canadas #1 consumer health brand, as well as the youtheory, Progressive, Sm...

Sisters of Saint Joseph of Philadelphia

We are a community of approximately 825 women religious. Originally founded in 1650 in LePuy, France, the Sisters of Saint Joseph came to Philadelphia in 1847. Through our many ministries, including educations, healthcare, social services and parish m...

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.